BR112023021803A2 - Composição farmacêutica compreendendo o composto smtp-7 - Google Patents

Composição farmacêutica compreendendo o composto smtp-7

Info

Publication number
BR112023021803A2
BR112023021803A2 BR112023021803A BR112023021803A BR112023021803A2 BR 112023021803 A2 BR112023021803 A2 BR 112023021803A2 BR 112023021803 A BR112023021803 A BR 112023021803A BR 112023021803 A BR112023021803 A BR 112023021803A BR 112023021803 A2 BR112023021803 A2 BR 112023021803A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
smtp
compound
treatment
additive
Prior art date
Application number
BR112023021803A
Other languages
English (en)
Portuguese (pt)
Inventor
Keiji Hasumi
Keiko Hasegawa
Naoko Nishimura
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of BR112023021803A2 publication Critical patent/BR112023021803A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
BR112023021803A 2021-04-20 2022-04-20 Composição farmacêutica compreendendo o composto smtp-7 BR112023021803A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021070892 2021-04-20
PCT/US2022/025462 WO2022226013A1 (en) 2021-04-20 2022-04-20 Pharmaceutical composition comprising the compound smtp-7

Publications (1)

Publication Number Publication Date
BR112023021803A2 true BR112023021803A2 (pt) 2024-01-23

Family

ID=81648879

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021803A BR112023021803A2 (pt) 2021-04-20 2022-04-20 Composição farmacêutica compreendendo o composto smtp-7

Country Status (9)

Country Link
US (1) US20240238252A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326258A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024525239A (cg-RX-API-DMAC7.html)
KR (1) KR20230173129A (cg-RX-API-DMAC7.html)
CN (1) CN117279634A (cg-RX-API-DMAC7.html)
AU (1) AU2022262593A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021803A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214630A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022226013A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240238248A1 (en) * 2021-05-10 2024-07-18 Ji Xing Pharmaceuticals Hong Kong Limited Pharmaceutical composition for use in treating cerebral infarction
WO2026092761A1 (zh) * 2024-11-04 2026-05-07 江苏恒瑞医药股份有限公司 包含smtp衍生物的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004224737A (ja) 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
JP4313049B2 (ja) 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
JPWO2007040082A1 (ja) 2005-10-06 2009-04-16 国立大学法人東京農工大学 腎炎治療又は予防用医薬組成物及びその製造方法
KR20080112184A (ko) 2006-03-27 2008-12-24 노우코우다이 티엘오 가부시키가이샤 트리프레닐페놀화합물과 트리프레닐페놀화합물의 제조방법,및 혈전용해촉진제
JP2008201688A (ja) * 2007-02-16 2008-09-04 Tms Co Ltd 皮膚老化防止剤、化粧料及び皮膚外用剤
JP5605659B2 (ja) * 2009-07-06 2014-10-15 国立大学法人東京農工大学 細胞保護剤
WO2011125930A1 (ja) 2010-04-02 2011-10-13 日本製薬株式会社 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤
JP7381035B2 (ja) * 2018-11-02 2023-11-15 学校法人昭和大学 Smtp一群又はsmtp-7の製造中間体及びその化学的製造方法
US20240238248A1 (en) * 2021-05-10 2024-07-18 Ji Xing Pharmaceuticals Hong Kong Limited Pharmaceutical composition for use in treating cerebral infarction

Also Published As

Publication number Publication date
KR20230173129A (ko) 2023-12-26
WO2022226013A1 (en) 2022-10-27
JP2024525239A (ja) 2024-07-11
CA3214630A1 (en) 2022-10-27
CN117279634A (zh) 2023-12-22
AU2022262593A1 (en) 2023-11-02
US20240238252A1 (en) 2024-07-18
EP4326258A1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
CL2023002383A1 (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
MX2022015613A (es) Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental.
DOP2024000119A (es) Composición farmacéutica que comprende un compuesto de quinazolina
BR112022010323A2 (pt) Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal
BR112023000770A2 (pt) Inibidor de egfr
BR112022009861A2 (pt) Derivado de cicloalquil ureia
SA523450286B1 (ar) مركب 4-أمينو كوينازولين
MY199903A (en) Combination therapy with controlled-release cnp agonists
BR112012025390B8 (pt) Composto de tetraidrobenzotiofeno ou sal do mesmo e seu uso no tratamento ou prevenção de hiperfosfatemia, bem como composição farmacêutica compreendendo o dito composto
BR112017022101A2 (pt) composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo
DOP2022000110A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
BR112018070586A2 (pt) compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos
SG11201908234WA (en) Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
BR112021017314A2 (pt) Uso de extrato de elaeocarpus sylvestris
Fabry et al. In-vitro activity of polyhexanide alone and in combination with antibiotics against Staphylococcus aureus
Halpern et al. Self-administered preoperative antiseptic wash to prevent postoperative infection after deep brain stimulation
BR112014030325A8 (pt) uso de composição contendo derivado de verbenona para a obtenção de produto destinado ao tratamento ou prevenção de doença cerebral degenerativa, alimento funcional para prevenir ou tratar doença neurodegenerativa e composto
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
MX2023000610A (es) Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
BR112019025478A8 (pt) Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer
BR112023023534A2 (pt) Composição farmacêutica para uso no tratamento de infarto cererbral
BR112017016278A2 (pt) agente preventivo e/ou terapêutico de doença imune
BR112018004249A2 (pt) composto, e, composição para prevenção ou tratamento de doenças trombóticas.
BR112022020865A2 (pt) Composição farmacêutica para prevenção ou tratamento de câncer compreendendo weissella cibaria wikim28 como ingrediente ativo
BR112014033088A2 (pt) composição para prevenção ou tratamento de colite compreendendo s-alil-l-cisteína como ingrediente ativo, e preparação médica compreendendo a mesma

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JI XING PHARMACEUTICALS HONG KONG LIMITED (CN)

B25D Requested change of name of applicant approved

Owner name: CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN)